您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Cisatracurium Besylate
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Cisatracurium Besylate
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Cisatracurium Besylate图片
CAS NO:96946-42-8
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
25mg电议
100mg电议

产品介绍
Cisatracurium besylate (51W89) 是一种非去极化神经肌肉阻滞剂,通过抑制神经肌肉传递来拮抗乙酰胆碱的作用。
Cas No.96946-42-8
别名顺苯磺酸阿曲库铵; 51W89
Canonical SMILESC[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C.C1=CC=C(C=C1)S(=O)(=O)[O-].C1=CC=C(C=C1)S(=O)(=O)[O-]
分子式C53H72N2O12.2C6H5O3S
分子量1243.48
溶解度≥ 62.174mg/mL in DMSO
储存条件4°C, protect from light
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Cisatracurium besylate (51W89) is a nondepolarizing neuromuscular blocking agent, antagonizing the action of acetylcholine by inhibiting neuromuscular transmission.

Cisatracurium Besylate (51W89) is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is a bisbenzyltetrahydroisoquinolinium agent with an intermediate duration of action. Cisatracurium Besylate (51W89) is one of the ten isomers of the parent molecule, atracurium. Moreover, cisatracurium represents approximately 15% of the atracurium mixture [1, 2].

References:
[1]. Dear, G.J., et al., Identification of urinary and biliary conjugated metabolites of the neuromuscular blocker 51W89 by liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom, 1995. 9(14): p. 1457-64.
[2]. Serra, C.S. and A.C. Oliveira, Cisatracurium: myographical and electrophysiological studies in the isolated rat muscle. Fundam Clin Pharmacol, 2006. 20(3): p. 291-8.